Scientists have described a novel, yet benign bone-covered growth's characteristics for doctors, so patients don't receive ...

An immunotherapy kept multiple myeloma at bay for over 80 percent of patients in a three-year clinical trial, and the FDA ...

G-CSF Limitations: These agents essentially overstimulate a bone marrow that is already damaged by chemotherapy. Furthermore, ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

Bone cancer in the leg, while relatively uncommon, presents with specific warning signs that warrant immediate medical attention. Understanding these symptoms enables individuals to seek prompt ...

Researchers from UC Davis and Lawrence Livermore National Laboratory developed and studied a new material — engineered bone marrow, or eBM. Engineered bone marrow offers a better way to study ...

Researchers at FIU are advancing a personalized approach to cancer treatment that is showing increasingly promising results ...